Kelly Q3 revenue slips, enterprise talent management pivots to growth

Kelly Services reported Q3 revenue of $927.2M, down 0.8% YoY. Enterprise talent management grew 2.4% to $496.1M, while science, engineering, and education segments declined. Gross margin improved to 21%. Q4 revenue guidance is flat to +1%. Shares fell 15% to $14.37.

Original reporting
Published Nov 5, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kelly Q3 revenue slips, enterprise talent management pivots to growth — source image
Decision brief

The 30-second read

$KELYABearishHigh
01

Why it matters

The earnings miss and cautious outlook are likely to keep the stock under pressure in the near term.

02

Market read

First‑report earnings release with material numbers and a 15% price move makes this a high‑value trading signal.

03

What to watch

Potential upside from the 7.9% rise in outcome‑based services and 11.6% jump in talent solutions revenue.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Kelly Services reported Q3 2026 results, showing a slight revenue decline and a sharp share drop.

Company-level read

Ticker impact

$KELYABearishHigh confidence
Context

Q3 revenue slipped 0.8% YoY to $927.2M and shares plunged 15% after earnings miss and cautious guidance.

Expected impact

likely further downside as investors price in earnings disappointment and modest outlook

Evidence & confidence

The company reported a revenue decline, a 15% share drop, and guidance that signals flat to modest growth, all of which are fresh, material facts.

Market effects

Staffing sector may face pressure as Kelly's miss signals broader demand weakness in science, engineering, and technology staffing.

U.S. staffing firms could see short-term sell pressure.

Limited to U.S. labor market outlook; minimal global impact.

Counterpoint

If the enterprise talent management segment's growth continues, the stock could rebound on a turnaround narrative.

Key entities

  • Kelly Services

    U.S. staffing firm (NASDAQ: KELYA).

Related articles

$KELYAMed

Kelly Services Inc (KELYA) Q3 2026 Earnings Call Highlights: ETM Turns Positive

Kelly Services (KELYA) reported Q3 2026 earnings, with CEO Chris Laden highlighting year-over-year growth across the business, driven by ETM. CFO Troy Anderson noted temporary demand pressure from a key ETM client but expects flat to 1% revenue growth in Q4. Gross margins normalized to 20%, with continued expansion expected. The company sees sustained momentum into 2027, citing broad demand increases and market share gains.

$KELYAHigh

KELLY SERVICES INC (KELYA): Third-Quarter 2026 Earnings

KELLY SERVICES INC (KELYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kelly Reports Third-Quarter 2026 Earnings TROY, Mich. (November 5, 2026) – Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2026. • Q3 revenue of $0.9 billion, down 0.8% year-over-year, an i

$KELYAMed

KELLY SERVICES INC (KELYA): Second-Quarter 2026 Earnings

KELLY SERVICES INC (KELYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kelly Reports Second-Quarter 2026 Earnings TROY, Mich. (August 6, 2026) – Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the second quarter of 2026. • Q2 revenue of $1.0 billion, with year-over-year decline im

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.